In this Section |
175816 Pharmacy provision of medical abortifacients in eight Mexican citiesMonday, October 27, 2008
Objective
Previous research suggests women frequently use misoprostol to self-induce abortion in Mexico. In many settings women obtain the medication from a pharmacy. The objective of the study is to better understand pharmacy staff provision of misoprostol in eight Mexican cities. Methods From a census of pharmacies provided by the Secretary of Economy, we selected 24 pharmacies in each city. Mystery client asked for a drug to interrupt a pregnancy. If the pharmacy vendor did not mentioned misoprostol spontaneously, the mystery clients asked directly for misoprostol. The mystery client recorded in a format the information provided by vendors after the interaction took place. Results Preliminary results from data obtained from two cities, shows that 18% of the vendors in Tuxlta and 11% in Guanajuato spontaneously recommended a drug to interrupt a pregnancy. The drug mentioned with more frequency was Cytotec a brand that contains misoprostol (75% in Guanajuato and 41% in Tuxtla), followed by drugs containing misoprostol and diclofenac (25% in Guanajuato and 21% in Tuxtla). When the mystery client directly inquired about Cytotec, 95% of vendors in Tuxtla and 100% in Guanajuato responded that had heard of the drug. However, only 28% of vendors in Tuxtla and 3% in Guanajuato recommended an effective dose to cause abortion. Conclusion Misoprostol recommendation is common at Mexican pharmacies. Recommendation of effective doses is higher in Guanajuato compare with Tuxtla. At this moment we have completed fieldwork in the other six cities and we will conduct data analysis to complete our study.
Learning Objectives: Keywords: Abortion, Latin American
Presenting author's disclosure statement:
Qualified on the content I am responsible for because: Designed instruments of the study, supervised field work, conducted dana analysis, and wrote the abstracts. I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
See more of: Abortion Related Topics
See more of: Population, Family Planning, and Reproductive Health |